NCT06018935RecruitingNot Applicable
A Cohort Establishment Study of Total Management of Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer)
Sichuan Cancer Hospital and Research Institute1 site in 1 country500 target enrollmentStarted: June 17, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Progress Freesurvival (PFS)
Study Overview
Brief Summary
A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Detailed Description
- To investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer);
- To study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures;
- The prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed;
- To study the efficacy and safety of PARPi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital;
- •Can cooperate with later follow-up.
Exclusion Criteria
- •Patients with other malignant tumors or previous history of other malignant tumors;
- •Have cognitive impairment.
Outcomes
Primary Outcomes
Progress Freesurvival (PFS)
Time Frame: Average six months after study completion.
The time from the start of treatment until the patient progresses further or dies.
Overall Survival (OS)
Time Frame: Average six months after study completion.
Measure the time from the start of treatment to the time of death.
Secondary Outcomes
- Occurrence of adverse reactions(Average six months after study completion.)
Investigators
Dengfeng Wang
Deputy chief
Sichuan Cancer Hospital and Research Institute
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Unknown
Comparising result of histopathology examination to frozen section for diagnosing ovarian malignancyCTRI/2024/04/065770JAWAHAR LAL NEHRU MEDICAL COLLEGE
Completed
Phase 2
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma PatientsOvarian NeoplasmsNCT00127920Gynecologic Oncology Associates20
Completed
Not Applicable
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4Ovarian CancerOvarian TumorNCT02326064Centre Hospitalier Departemental Vendee221
Recruiting
Not Applicable
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypePrimary Peritoneal CancerFallopian Tube CancerOvarian CancerNCT05574673Nordic Society of Gynaecological Oncology - Clinical Trials Unit350
Recruiting
Phase 2
HRD Tests for Ovarian cancEROvarian CancerNCT06152731Centre Francois Baclesse88